Such devices, once validated, could guide therapy: for instance, if the probe shows high tissue oxygen but poor utilization (indicative of mitochondrial dysfunction), the team might intensify mitochondrial support interventions (208)
BPC-157 may be less appropriate for those with a history of cancer or active malignancy, individuals uncomfortable with the investigational nature of peptide therapy, people unable to commit to consistent daily administration for 4-8 weeks, those seeking instant results rather than gradual healing, and anyone who cannot source pharmaceutical-grade products from reputable suppliers
Not as magic bullets
At 32 weeks, phase 2 studies of Cagrilintide plus Semaglutide show weight losses of more than 20%, which is a lot better than the results of monotherapy
13 A maculopapular rash, malar rash, photosensitivity, and alopecia are common skin manifestations, seen in 72% of patients
Patients experienced improvement in pain, reduced frequency of headache, and improvement in mood